Brief: Virios Therapeutics Announces Positive Data of Drug Combination To Treat Multiple Long-Covid Symptoms In A Study

Dogwood Therapeutics

17/07/2023 12:18

July 17 (Reuters) - Virios Therapeutics Inc  VIRI.O :
    * VIRIOS THERAPEUTICS ANNOUNCES POSITIVE DATA DEMONSTRATING
IMPROVEMENT IN MULTIPLE LONG-COVID SYMPTOMS FOLLOWING TREATMENT
WITH A COMBINATION OF VALACYCLOVIR AND CELECOXIB IN AN
EXPLORATORY, OPEN-LABEL, PROOF OF CONCEPT STUDY
    * VIRIOS THERAPEUTICS INC - TREATMENT WITH VAL/CEL WAS
GENERALLY
WELL TOLERATED
    * VIRIOS THERAPEUTICS - OBSERVED SAFETY PROFILE CONSISTENT
WITH
KNOWN SAFETY PROFILES OF VALACYCLOVIR AND CELECOXIB
    * VIRIOS THERAPEUTICS - THERE WERE NO SERIOUS ADVERSE EVENTS
OBSERVED IN STUDY
    * VIRIOS THERAPEUTICS - ONLY ONE TREATED PATIENT
DISCONTINUED
TREATMENT DUE TO ADVERSE EVENTS, POSSIBLY RELATED TO VAL/CEL
TREATMENT
    * VIRIOS THERAPEUTICS- PLANS TO MEET FDA IN H2 2023 TO
DISCUSS
OPENING AN IND APPLICATION
    * VIRIOS- IND APPLICATION TO FORMALLY ASSESS TREATMENT OF
SYMPTOMS
ASSOCIATED WITH PASC USING A FIXED DOSE COMBINATION OF
VALACYCLOVIR AND CELECOXIB

Source text for Eikon:  ID:nGNX1C22V8 
Further company coverage:  VIRI.O 

 ((Reuters.Briefs@thomsonreuters.com;))